3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
4
Smoldering Multiple Myeloma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Leukemia, Promyelocytic, Acute
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Lenalidomide
7
Dexamethasone
5
Calcium Dobesilate
4
elotuzumab
2
Denosumab
2
siltuximab
1
piperine
1
ixazomib
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
daratumumab
1
auricularum
1
Urination
1
Receptors, Interleukin-6
1
Peripheral Blood Stem Cell Transplantation
1
PVX-410 vaccine
1
Nivolumab
1
Melphalan
1
Maintenance
1
Interleukin 1 Receptor Antagonist Protein
1
In Situ Hybridization, Fluorescence
1
Immunotherapy, Active
1
IPH-2101
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Cytogenetic Analysis
1
Cyclophosphamide
1
Curcumin
1
Celecoxib
1
BHQ880
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Smoldering Multiple Myeloma
×
Maintenance
×
Clear all
NCT00480363
2013-07-31
QUIREDEX
PETHEMA Foundation
Phase 3
Completed
120 enrolled